BTK degradation as a novel therapeutic strategy for relapsed CNS lymphoma

James Rubenstein, MD, PhD, University of California San Francisco, San Francisco, CA, shares some insights into the promise of BTK degradation as a novel therapeutic approach for patients with relapsed CNS lymphoma. Dr Rubenstein explains the need for more potent treatment strategies in this disease, highlighting some of the major pathways involved. Following this, Dr Rubenstein discusses the mechanism of action of BTK degraders, commenting on two agents which have demonstrated promising preclinical activity: NX-2127 and NX-5948. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.